Bioaffinity Technologies, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 29, 2025, details a capital raise and significant corporate actions by Bioaffinity Technologies, Inc. (BIAF), a Delaware corporation. The filing addresses the consummation of a public offering, a recent reverse stock split, and the company's status regarding Nasdaq listing compliance.
Key Financial Metrics and Capital Structure
- Offering Proceeds: The company raised approximately $4.8 million in gross proceeds from a best efforts public offering.
- Securities Issued: 1,047,694 shares of Common Stock at $2.50 per share and pre-funded warrants to purchase 874,067 shares at $2.493 per share.
- Transaction Costs: Placement agent fees totaled 8.0% of gross proceeds, plus $120,000 in reimbursed expenses.
- Outstanding Shares: Following the offering and certain warrant exercises, 3,100,402 shares of Common Stock were outstanding as of the filing date.
- Balance Sheet Impact: A 1-for-30 reverse stock split is expected to eliminate approximately $4 million in warrant-related derivative liabilities, reclassifying them to stockholders' equity. Additionally, warrant amendments are expected to increase equity by approximately $2.8 million.
- Recent Cash Inflows: Since June 30, 2025, the company received approximately $1.3 million from warrant exercises and $1.2 million from a private placement in August 2025.
Material Changes and Corporate Actions
- Reverse Stock Split: A 1-for-30 reverse stock split became effective on September 18, 2025, to address Nasdaq's Minimum Bid Price Requirement. The company has maintained compliance for seven consecutive trading days post-split.
- Nasdaq Compliance: The company previously received notices of non-compliance with the Minimum Bid Price Requirement (below $1.00) and the Continued Listing Equity Requirement (equity below $2.5 million). Following the capital raise and equity reclassifications, the company believes it has regained compliance with the $2.5 million equity requirement.
- Lock-Up Provisions: Executive officers and directors are subject to a 60-day lock-up period. The company is restricted from issuing new equity for 30 to 45 days and from variable rate transactions for 6 months, subject to exceptions.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Funds from the $4.8 million offering are designated for working capital and general corporate purposes.
- Delisting Risk Mitigation: The company successfully appealed a scheduled delisting, securing an extension until October 2, 2025, to demonstrate compliance with Nasdaq rules. The recent capital raise and reverse split are central to this compliance strategy.
- Warrant Terms: Pre-funded warrants are immediately exercisable at $0.007 per share. Beneficial ownership limits restrict exercise to 4.99% (or 9.99% with notice) of outstanding shares.
Investor Verification Checklist
- Confirm Nasdaq's official written confirmation of the company's regained compliance with the Continued Listing Equity Requirement.
- Verify the final net proceeds after deducting all offering expenses and placement agent fees.
- Monitor the company's ability to maintain the Minimum Bid Price Requirement through the October 2, 2025 deadline.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and exceptions to the lock-up periods.
- Assess the impact of the $4 million derivative liability reclassification on the upcoming quarterly financial statements.